3 Essential Components Of Successful Renal And Hepatic Impairment Studies

Impaired kidney or liver function can change how a drug is absorbed, metabolized, and cleared from the body, which means dosing that's safe for a healthy patient may not be safe for someone with renal or hepatic disease. This makes renal and hepatic impairment studies a critical, and often required, step in confirming that a new therapy can be dosed safely and effectively across the full range of patients.

These studies come with unique challenges: complex patient populations with multiple medications, lab values that don't align with healthy-volunteer norms, and logistical hurdles like coordinating around dialysis schedules. For sponsors planning these impairment studies, the priority is building a protocol and site strategy grounded in real-world knowledge of these patient populations, so that dosing guidance is both scientifically sound and achievable to collect efficiently.